NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Endo International plc (NASDAQ: ENDP) concerning possible violations of federal securities laws. On June 8, 2017, the U.S. Food and Drug Administration (the “FDA”) requested Endo pull its opioid painkiller OPANA ER off the U.S. market. According to the FDA, Opana’s “high risk of abuse and potential to help spread HIV and hepatitis C” necessitated its removal from the market. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.